Derivatives and methods of treating hepatitis B infections

A compound of Formula IIIa:

• or a pharmaceutically acceptable salt thereof, wherein
• Y is —C(O)— or —SO2—;
• R1 is C1-C9-heteroaryl which is optionally substituted with 1 or 2 groups each independently selected from —OH, halo, C1-C6-alkyl, C1-C6-haloalkyl, —O—C1-C6-alkyl, C1-C6-alkyl-OH, CN, and C(O)H;
• R2 is, at each occurrence, independently selected from H, —OH, halo, C1-C6-alkyl, C1-C6-haloalkyl, —O—C1-C6-alkyl, and C1-C6-alkyl-OH;
• R3 is selected from H, —OH, halo, C1-C6-alkyl, C1-C6-haloalkyl, —O—C1-C6-alkyl, and C1-C6-alkyl-OH;
• R4 is (CR8R9)p—C6-C12-aryl, optionally substituted with 1, 2, or 3 groups, each independently selected from —OH, halo, CN, C1-C6-alkyl, C1-C6-haloalkyl, —O—C1-C6-alkyl, and C1-C6-alkyl-OH;
• R7 is selected from H, C1-C6-alkyl, and C1-C6-alkyl-OH;
• R8 is, at each occurrence, independently selected from H, —OH, halo, C1-C6-alkyl, C1-C6-haloalkyl, —O—C1-C6-alkyl, and C1-C6-alkyl-OH;
• R9 is, at each occurrence, independently selected from H and C1-C6-alkyl;
• and
• p is 0, 1, 2, 3, or 4.